Relative Bioavailability of Single Dose BI 10773 Co-administered With Multiple Doses of 600 mg Gemfibrozil Bid Compared to Single Dose Treatment of BI 10773 Alone in Healthy Volunteers - a Phase I, Open-label, Randomised, 2-way Crossover Trial

Trial Profile

Relative Bioavailability of Single Dose BI 10773 Co-administered With Multiple Doses of 600 mg Gemfibrozil Bid Compared to Single Dose Treatment of BI 10773 Alone in Healthy Volunteers - a Phase I, Open-label, Randomised, 2-way Crossover Trial

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2014

At a glance

  • Drugs Empagliflozin (Primary) ; Gemfibrozil
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 05 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 05 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top